Toxicity management after chimeric antigen receptor T cell therapy: One size does not fit 'ALL'

Nature Reviews Clinical Oncology

Volumn 15, Issue 4, 2018, Pages 218-

  Teachey, David T ^a   Bishop, Michael R ^b   Maloney, David G ^c   Grupp, Stephan A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXICABTAGENE CILOLEUCEL; CORTICOSTEROID; DEXAMETHASONE; FILGRASTIM; INTERLEUKIN 6 ANTIBODY; JCAR 014; JCAR 017; LEVETIRACETAM; METHYLPREDNISOLONE; SILTUXIMAB; TISAGENLECLEUCEL T; TOCILIZUMAB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY; CONSENSUS; CYTOKINE RELEASE SYNDROME; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HEMOPHAGOCYTIC SYNDROME; HUMAN; LETTER; MACROPHAGE ACTIVATION SYNDROME; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEIZURE; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; BIOLOGICAL THERAPY;

CELL- AND TISSUE-BASED THERAPY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; RECEPTORS, CHIMERIC ANTIGEN;

EID: 85044209108     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2018.19     Document Type: Letter

References (18)

1. Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy-Assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47-62 (2018).
2. Hough, R. et al. Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003. Br. J. Haematol. 172, 439-451 (2016).
3. Wildes, T. M., Goede, V. & Hamlin, P. Personalizing therapy for older adults with lymphoid malignancies: options and obstacles. Am. Soc. Clin. Oncol. Educ. Book, e240-e248 (2014).
4. Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl Med. 303, ra139 (2015).
5. Buechner, J. et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia: an update to the interim analysis. in 22nd Congress of the European Hematology Association S476 (Madrid, Spain, 2017).
6. Schuster, S. J. et al. Global trial of the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma: an interim analysis of the JULIET study. in 22nd Congress of the European Hematology Association LB2604 (Madrid, Spain, 2017).
7. Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664-679 (2016).
8. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
9. Fitzgerald, J. C. et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit. Care Med. 45, e124-e131 (2017).
10. Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy. Blood 130, 2295-2230 (2017).
11. Turtle, C. J. et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J. Clin. Oncol. 35, 3010-3020 (2017).
12. Kochenderfer, J. N. et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129-4139 (2013).
13. Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188-195 (2014).
14. Gilbert, M. J. Severe neurotoxicity in the phase 2 trial of JCAR015 in adult B-ALL (ROCKET study): analyses of patient, protocol and product attributes. in 32nd Annual SITC Meeting (National Harbor, MD, USA, 2017).
15. Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517-528 (2015).
16. Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518 (2013).
17. Brisse, E., Matthys, P. & Wouters, C. H. Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. Br. J. Haematol. 174, 175-187 (2016).
18. Horne, A. et al. How to treat involvement of the central nervous system in hemophagocytic lymphohistiocytosis? Curr. Treat. Opt. Neurol. 19, 3 (2017).